Targeting pathogenic disease mechanisms via cytokine blockade has revolutionized the treatment of IMIDs, particularly following the pioneering application of TNF inhibitors in the treatment of rheumatoid arthritis (RA) [5]. Here, TNF is linked to rheumatoid arthritis.